Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma.

BMC Gastroenterol · 2026 · PMC13064003 · PMID 41776425

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

did not reach statistical significanceP = 0.083so close (0.05 < p ≤ 0.1)

Notably, CEA levels significantly declined only in the TACE+dual-drug group ( P < 0.001), whereas the reduction in the TACE + RFA group did not reach statistical significance ( P = 0.083).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.